Text Size

Assessment of MDD Management in Andalusia (PismaEP)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01510886
First received: January 12, 2012
Last updated: October 29, 2012
Last verified: October 2012
History of Changes
  Purpose

The main objectives of this study are to describe medical professionals responsible of the management of patients with MDD in a representative region of Andalusia (in terms of type of sites managing the disease, and referral to SC criteria); Describe MDD patient characteristics at inclusion in the PISMA-Ep Study; and to evaluate those factors associated to a higher incidence of referral from PC to SC.


Condition
MDD Management Strategies

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Assessment of MDD Management Strategies in Andalusia: A Sub-analysis of the PismaEP Study

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Number of Visits to Primary Care [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Number of Visits to Secondary Care [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Number of Referrals [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Demographics [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Type of site [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Type of therapeutic strategy [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Type of disease [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]
  • Severity of disease [ Time Frame: From Jan 2010 to Jan 2011 ] [ Designated as safety issue: No ]

Enrollment: 52693
Study Start Date: June 2012
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)

Detailed Description:

Assessment of MDD management strategies in Andalusia: A Sub-analysis of the PismaEP Study

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

MDD patients treated in Primary Care or Secondary Care in the Region of Granada and recruited for the PISMA-Ep Study

Criteria

Inclusion Criteria:

  • MDD Diagnosis Participants of the PismaEP study 18 yo. or older

Exclusion Criteria:

  • No specific exclusion criteria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01510886

Locations
Spain
Research Site
Granada, Spain
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Jorge Cervilla, MD Hospital San Cecilio
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01510886     History of Changes
Other Study ID Numbers: NIS-NES-XXX-2011/3, PismaEP
Study First Received: January 12, 2012
Last Updated: October 29, 2012
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by AstraZeneca:
MDD, management, Andalusia, Database, PismaEP

ClinicalTrials.gov processed this record on May 16, 2013